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A B S T R A C T   
The AKT kinase family is a high-profile target for cancer therapy. Despite their high degree of homology the three 
AKT isoforms (AKT1, AKT2 and AKT3) are non-redundant and can even have opposing functions. Small-molecule 
AKT inhibitors affect all three isoforms which severely limits their usefulness as research tool or therapeutic. 
Using AKT2-specific nanobodies we examined the function of endogenous AKT2 in breast cancer cells. Two AKT2 
nanobodies (Nb8 and Nb9) modulate AKT2 and reduce MDA-MB-231 cell viability/proliferation. Nb8 binds the 
AKT2 hydrophobic motif and reduces IGF-1-induced phosphorylation of this site. This nanobody also affects the 
phosphorylation and/or expression levels of a wide range of proteins downstream of AKT, resulting in a G0/G1 
cell cycle arrest, the induction of autophagy, a reduction in focal adhesion count and loss of stress fibers. While 
cell cycle progression is likely to be regulated by more than one isoform, our results indicate that both the effects 
on autophagy and the cytoskeleton are specific to AKT2. By using an isoform-specific nanobody we were able to 
map a part of the AKT2 pathway. Our results confirm AKT2 and the hydrophobic motif as targets for cancer 
therapy. Nb8 can be used as a research tool to study AKT2 signalling events and aid in the design of an AKT2- 
specific inhibitor.   
1. Introduction 
The phosphoinositide 3-kinase (PI3K)-AKT pathway is the most 
frequently over-activated pathway in human cancer [1]. Multiple ge-
netic aberrations have been identified in members of this pathway. Ex-
amples include the amplification or mutation of receptor tyrosine 
kinases (RTKs) such as EGFR and HER2, activating mutations in PI3K 
and PDK1, and loss of PTEN [2,3]. These events result in increased ac-
tivity of the serine/threonine protein kinase AKT (a.k.a. protein kinase 
B) [2,4]. AKT is activated by phosphorylation of threonine-309 in the 
activation loop of the catalytic domain and serine-474 in the C-terminal 
hydrophobic motif (HM) by PDK1 and mTORC2, respectively. Phos-
phorylation of both sites enhances AKT stability and is required for 
maximal catalytic activity [5–7]. Well over a hundred AKT substrates 
spanning several functional classes (protein and lipid kinases, regulators 
of the cell cycle, metabolic enzymes, transcription factors, …) have been 
identified. Some of these substrates (GSK3α/β, FoxO and mTORC1) are 
major signalling nodes on their own. 
By integrating a wide array of extracellular signals, AKT, as a master 
kinase regulates cell proliferation, survival, growth, migration and 
metabolism [5]. This relation of AKT to various hallmarks of cancer, 
together with the high incidence (>50 %) of AKT hyper-activation in 
cancer have made this kinase a high-profile target. This has led to the 
development of several small-molecule inhibitors, some of which have 
already made it to clinical trials, albeit with limited success [2,8–11]. 
Both ATP-competitive and allosteric AKT inhibitors have been devel-
oped. For ATP-competitive inhibitors, the lack of specificity for AKT is a 
major issue, which comes as no surprise given the high degree of 
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similarity of the AKT catalytic domain with such domains from other 
kinases of the AGC kinase family [12,13]. Allosteric AKT inhibitors, such 
as MK-2206, which target the PH-domain, show more potential. How-
ever, these suffer from the drawback that they affect all AKT isoforms 
(AKT1/PKBα, AKT2/PKBβ and AKT3/PKBγ), testifying to the difficulty 
of developing specific AKT inhibitors [14]. 
The three AKT isoforms are encoded by separate genes and display 
up to 82 % sequence identity[15]. Despite their highly similar se-
quences, the isoforms are non-redundant. This was reported in studies 
using mice with individual knockouts (KO) of AKT isoforms and has 
been amply confirmed in in vitro studies [3,16–34]. To complicate 
matters further, their role is also context-dependent and in certain cases 
opposed to one another. The exact mechanisms that contribute to 
isoform-specificity have not been fully elucidated, but distinct subcel-
lular localization, differences in relative expression levels and intrinsic 
kinetic properties, specific (in)activation and mutation of the isoforms 
are likely to play a role [3,6,26,35–37]. A striking example of 
isoform-specific functions are the roles of AKT1 and AKT2 in breast 
cancer, where AKT2 enhances migration and invasion of cancer cells, 
while AKT1 has the opposite function [21,38–40]. 
Such observations help to explain the limited success of AKT in-
hibitors in clinical trials and underline the need for a detailed study of 
the complex AKT signalling cascades. Mapping each isoform’s pathway 
and developing isoform-specific inhibitors could be the next step in 
tailoring cancer treatment to be most beneficial for the patient. 
In this study we focus on the role of AKT2 in the MDA-MB-231 breast 
cancer cell model. Instead of relying on genetic approaches to interfere 
with AKT2, we use nanobodies (Nbs) to target this isoform. Nbs are the 
antigen-binding fragment of heavy-chain-only antibodies. They consist 
of a single domain, are small (15 kDa) and highly stable proteins that 
interact with their antigen with high affinity and specificity [41]. 
Additionally, Nbs remain functional when expressed in the reducing 
cytoplasm of mammalian cells, which allows their use for modulating 
endogenous proteins in a relevant context [42–49]. The AKT2 nano-
bodies were obtained by immunization of an alpaca with in vitro 
phosphorylated AKT2 and were previously shown to only interact with 
the AKT2 isoform [50]. 
Here, we show that the AKT2 Nbs are high-affinity interactors, which 
interact only with the AKT2 isoform when stably expressed in MDA-MB- 
231 cells that express all three AKT isoforms. Nbs 8 and 9 have a cyto-
toxic/cytostatic effect that is unrelated to apoptosis. We show that Nb8 
reduces phosphorylation of the AKT2 HM in IGF-1-stimulated cells and 
use a (phospho)proteomics approach to map the downstream effects. 
Our results indicate that AKT2 is a major regulator of the cell cycle, 
organization of the actin cytoskeleton and autophagy. Nb8 has allowed 
us to map a part of the AKT2-specific signalling pathway, identified the 
HM as a therapeutic epitope and further strengthened AKT2 as a bona- 
fide target for cancer therapy. This Nb is thus a promising new tool 
which can be applied, as a complementary approach to genetic ap-
proaches, in various contexts to study the function of this AKT isoform 
and could be used in the rational design of the first AKT2-specific in-
hibitor by, for instance, co-crystallization and medicinal chemistry [47]. 
2. Methods 
2.1. Antibodies 
See Supplementary methods for detailed information on the anti-
bodies used in this study. 
2.2. Production and purification of recombinant FL-AKT2 
The production of recombinant FL-AKT2 was performed as described 
previously [50]. Briefly, BL21 E. coli were heat-shock transformed and a 
culture was grown in Terrific Broth (TB, 16.9 mM KH2PO4, 71.9 mM 
K2HPO4.3H2O, 2 mM MgCl2, 12 g Tryptone, 24 g yeast extract, 4% 
glycerol, 1% glucose pH 7.2) to OD600≥2, expression was induced with 
0.5 mM IPTG and the cultures were incubated ON at 20 ◦C in a shaking 
incubator. Cells were lysed using a French press and sonication, debris 
was pelleted (11,000 x g for 20 min at 4 ◦C) and the supernatant (SN) 
was loaded onto a column containing Chitin beads (New England Bio-
labs). After washing the beads, proteins were eluted by ON incubation 
with 50 mM DTT and purified by anion exchange chromatography (GE 
Healthcare). Purity was assessed by SDS-PAGE and Coomassie staining. 
2.3. Production of recombinant AKT2 Nbs 
WK6 E. coli were heat-shock transformed with pMECS-Nb plasmids 
and grown in TB at 37 ◦C until an OD600 of 0.6− 0.8 was reached. Nb 
expression was induced by adding 1 mM IPTG and cultures were incu-
bated ON at 28 ◦C. Nbs in the pMECS vector are expressed with an N- 
terminal PelB signal sequence, resulting in periplasmatic localization. 
Cells were pelleted (11,000 x g for 20 min at 4 ◦C) and Nbs were 
extracted through osmotic shock using Tris-EDTA-Sucrose (TES, 0.2 M 
Tris, 0.5 mM EDTA, 0.5 M sucrose, pH 8.00). Protein concentration of 
the resulting periplasmatic extract was measured using the Bradford 
assay (Bio-Rad Laboratories). 
2.4. Bio-layer interferometry and data processing 
All experiments were run on an Octet RED96 system (ForteBio) at 25 
◦C. Anti-Penta-HIS biosensors (HIS1K, ForteBio) were pre-wet in kinetics 
buffer (KB, PBS (Gibco, Thermo Fisher) with 0.1 % (w/v) BSA) for at 
least 10 min. Loading solutions, containing 10 μg/mL protein, were 
prepared by diluting the Nb-containing periplasmatic extracts in KB. All 
samples were dispensed into a 96-wellplate (Greiner Bio-One, 655209) 
at a volume of 200 μl. A single kinetics run entailed the following steps: 
Biosensor Regeneration (5 s in 0.5 M H2SO4 followed by 5 s in KB, for 
three cycles), Baseline (60 s in KB), Loading (300 s in loading solution), 
Baseline (60 s in KB), Association (300 s in KB containing purified FL- 
AKT2) and Dissociation (600 s in KB). Flow rate was set to 1000 for 
all steps. For Association, four FL-AKT2 concentrations were included 
(twofold dilutions starting at 25 nM FL-AKT2 for Nbs 5 and 9 or starting 
at 800 nM for Nb8) and a single reference well without FL-AKT2 for 
background subtraction. Data was processed (software version 9.0.0.4) 
using the reference well for subtraction, the baseline was aligned to the 
y-axis (last 5 s of the Baseline step) and Savitzky-Golay filtering was used 
to reduce noise. KD values were generated by fitting (global fit using 
curves from all AKT2 concentrations) the full association and dissocia-
tion steps to a 1:1 kinetic model. 
2.5. Cell culture and transduction 
For maintenance, MDA-MB-231 (ATCC® HTB-26™) cells were 
grown at 37 ◦C in a humidified 10 % CO2 incubator. The cells were 
cultured in DMEM supplemented with 10 % foetal bovine serum and 100 
IU/mL penicillin and 10 μg/mL streptomycin (medium and supplements 
from Gibco, Thermo Fisher Scientific). Prior to experiments, all cell lines 
were tested and found negative for mycoplasma contamination using 
PlasmoTest™ (InvivoGen). Stable cell lines expressing the AKT2 Nbs 
and the EGFP Nb were generated using the Lenti-X Tet-On Advanced 
Inducible Expression System (clontech) as described previously [44]. 
2.6. Immunofluorescence and microscopy 
Coverslips were coated with 50 μg/mL rat tail type I collagen (BD 
Biosciences) in PBS (with Ca2+ and Mg2+) for 1 h at 37 ◦C. MDA-MB-231 
cells were seeded at a density <50 % for Cyclin D1 detection and 60–80 
% for all other experiments. 24 h post-seeding, Nb expression was 
induced with 500 ng/mL Dox (Duchefa Biochemie, D0121) or the cells 
were treated with 5 μM MK-2206 (Selleckchem). Immunostaining was 
performed 24 h later. For visualization of autophagic vesicles and 
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mitochondria, cells were treated with 10 μM Chloroquine for 4 h and 
incubated with Cyto-ID® green detection reagent (Enzo Life Sciences, 
ENZ-KIT175) and 0.1 μM MitoTracker™ Orange CMTMRos (Thermo 
Fisher Scientific, M7510) according to the manufacturer’s instructions. 
Cells were fixed with 3% paraformaldehyde for 25 min, permeabilized 
with 0.2 % Triton X-100 for 5 min and incubated with 100 mM glycine 
for 20 min. Each incubation step was followed by at least three washing 
steps with PBS (with Ca2+ and Mg2+). Coverslips were incubated with 
primary and secondary antibodies (1 h at 37 ◦C or 30 min at room 
temperature (RT) for primary Ab and secondary Ab, respectively), nuclei 
were stained with 0.4 μg/mL DAPI (Sigma Aldrich, D9542) and Acti- 
stain 670 Phalloidin (Cytoskeleton, PHDN1-A) was used to visualise F- 
actin. Coverslips were mounted onto microscopy slides using Vecta-
shield antifade mounting medium (Vector Laboratories, H-1000) and 
sealed using nail polish. Images were captured using a Zeiss Axiovert 
200 M fluorescence microscope with Apotome module (Zeiss x63 1.4-NA 
Oil Plan-Apochromat objective, Carl Zeiss) and Axiovision 4.5 software 
(Zeiss) or an Olympus IX81 Fluoview 1000 confocal laser scanning mi-
croscope (Olympus x60 1.36-NA Oil UplanSApo objective, Olympus, 
Tokyo, Japan) with FluoView FV 1000 software (Olympus). Images were 
analyzed using ImageJ. For quantifying Cyclin D1 co-localization with 
DAPI, the Coloc2 plugin was used. A one-way ANOVA with tukey’s 
multiple comparison test (GraphPad Prism v5.00) was used to compare 
Manders colocalization coefficient with costes thresholding between cell 
lines. Representative for 85 cells per cell line collected over three 
repeated experiments. Autophagic vesicles were counted using ImageJ. 
Focal Adhesion count was determined according to Horzum et al. [51]. 
A one-way ANOVA with dunnett’s multiple comparison test (GraphPad 
v5.00) was used to determine significant differences in the average 
number of focal adhesions present in cells. 
2.7. Co-immunoprecipitation of AKT2 using intrabodies 
Stable cell lines expressing the AKT2 Nbs and EGFP Nb were seeded 
in T75 cell culture flasks and Nb expression was induced by adding 500 
ng/mL Dox. After 24 h, cells were lysed in ice-cold Tris Lysis buffer (20 
mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 200 μg/mL 
protease inhibitor cocktail pH 7.5). Cell debris was pelleted and protein 
concentration determined using the Bradford assay. 1 mg WCL was 
incubated with 10 μl settled anti-V5-agarose beads (A7345, Sigma 
Aldrich) for 1 h at 4 ◦C with end-over-end rotation. The beads were 
washed three times and proteins were eluted in Laemmli SDS sample 
buffer (5% SDS, 20 % glycerol, 0,2% bromophenol blue, 5% β-mercap-
toethanol, 65 mM Tris-HCl pH 6.8) by heating the beads to 95 ◦C for 5 
min. Eluates were analysed by SDS-PAGE and Western blotting. D6G4 
was used to detect AKT2 and Nbs were detected using an anti-V5 Ab 
(Invitrogen, 1296025). 
2.8. XTT assay 
Stable MDA-MB-231 cell lines expressing the AKT2 Nbs or EGFP Nb 
were detached using Trypsin-EDTA (Gibco, Thermo Fisher Scientific) 
and re-seeded at 6,000 cells per well in 96-wellplates (Greiner Bio-One, 
655160). A separate plate was used for each time point (24 h, 48 h and 
72 h). 500 ng/mL Dox was added to induce Nb expression. An internal 
control condition without Dox and background correction wells con-
taining only medium (no cells) were also included. After incubation 
(24− 72 h) 50 μl of activated XTT solution (XTT cell proliferation kit II, 
Roche) was added to all wells and the OD was measured at 475 nm and 
660 nm, immediately (background), 4 h and 6 h after adding the solu-
tion. Specific absorbance was obtained by subtracting the values from 
background wells and non-specific readings (OD at 660 nm). Values 
were normalized for the internal control and the EGFP Nb-expressing 
cells. Data was gathered from three independent experiments. A one- 
way ANOVA with tukey’s multiple comparison test (GraphPad Prism v 
5.00) was used to compare all time points within a single cell line or a 
single time point between all cell lines. 
2.9. Caspase-3 detection 
Stable MDA-MB-231 cell lines expressing AKT2 Nbs or the EGFP Nb 
were seeded in 6-wellplates at a density of 75,000 cell per well and Nb 
expression was induced by adding 500 ng/mL Dox. Cells were lysed with 
ice cold Tris Lysis buffer, immediately, 24 h, 48 h and 72 h after adding 
Dox. Staurosporine-treated (10 μM, 24 h) cells were included as positive 
control. Protein concentration in the WCL was determined by Bradford 
assay and a 10 μg sample was analysed by SDS-PAGE and Western 
blotting. The Caspase-3 Ab used (Cell Signaling Technology, 9662) 
detected both full-length Caspase-3 and the 17/19 kDa fragments. Vin-
culin (hVIN-1, Sigma Aldrich) was used as loading control and Nbs were 
detected through their V5-tag. 
2.10. AKT2 hydrophobic motif phosphorylation 
MDA-MB-231 cell stably expressing Nb8 were seeded in a 6-wellplate. 
Cells were serum starved for 48 h and Nb expression was induced with 
500 ng/mL Dox for 24 h. A control condition of serum starved cells 
without Dox was included. Cells were stimulated with 5 ng/mL IGF-1 for 
1 min, 5 min, 15 min or 30 min and lysed using ice cold RIPA lysis buffer 
(25 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1 
% SDS, 1 mM PMSF, 200 μg/mL protease inhibitor cocktail mix, pH 7.6) 
with phosphatase inhibitors (PhosSTOP™, Roche, 1 tablet/10 ml buffer). 
A 10 μg sample was analysed by SDS-PAGE and western blotting. AKT2 
and p-AKT2 S474 were detected using D6G4 and D3H2, respectively. 
Vinculin was used as loading control and Nb8 was detected using an anti- 
V5-tag Ab. Signal intensity was quantified using ImageJ. A one-way 
ANOVA (GraphPad Prism v5.00) was used to compare signal intensity 
in Nb8-expressing cells with un-induced counterparts. 
2.11. (Phospho)proteomics analysis 
2.11.1. Sample preperation 
Stable MDA-MB-231 cells expressing Nb8 or the EGFP Nb were 
serum-starved for 48 h and treated with Dox (500 ng/mL) for 24 h prior 
to IGF-treatment (5 ng/mL, 5 min) and lysis. Cells were scraped and 
lysed in a urea lysis buffer containing 9 M urea, 20 mM HEPES pH 8.0 
and PhosSTOP™ phosphatase inhibitor cocktail (Roche, 1 tablet/10 ml 
buffer). The samples were sonicated with 3 pulses of 15 s at an amplitude 
of 20 % using a 3 mm probe, with incubation on ice for 1 min between 
pulses. After centrifugation for 15 min at 20,000 x g at RT to remove 
insoluble components, proteins were reduced by addition of 5 mM DTT 
and incubation for 30 min at 55 ◦C and then alkylated by addition of 10 
mM iodoacetamide and incubation for 15 min at RT in the dark. The 
protein concentration was measured using a Bradford assay and, from 
each sample, 4 mg protein was used to continue the protocol. Samples 
were further diluted with 20 mM HEPES pH 8.0 to a final urea con-
centration of 4 M and proteins were digested with 40 μg LysC (Wako) (1/ 
100, w/w) for 4 h at 37 ◦C. Samples were diluted to 2 M urea and 
digested with 40 μg trypsin (Promega) (1/100, w/w) overnight at 37 ◦C. 
The resulting peptide mixture was acidified by addition of 1% tri-
fluoroacetic acid (TFA) and after 15 min incubation on ice, samples were 
centrifuged for 15 min at 1,780 x g at room temperature to remove 
insoluble components. Next, peptides were purified on SampliQ SPE C18 
cartridges (500 mg, Agilent). Columns were first washed with 5 ml 100 
% acetonitrile (ACN) and pre-equilibrated with 15 ml of solvent A (0.1 % 
TFA in water/ACN (98:2, v/v)) before samples were loaded on the col-
umn. After peptide binding, the column was washed again with 5 ml of 
solvent A and peptides were eluted twice with 700 μl elution buffer (0.1 
% TFA in water/ACN (20:80, v/v)). The eluted peptides were divided in 
two parts: 100 μl was dried completely in a speedvac vacuum concen-
trator for shotgun analysis, while the remainder was used for phos-
phopeptide enrichment. Phosphopeptides were enriched with 
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MagReSyn® Ti-IMAC beads according to the manufacturer’s in-
structions with slight modifications. Briefly, 100 μl MagReSyn® Ti- 
IMAC beads (per sample) were washed twice with 70 % EtOH, once 
with 1% NH4OH and three times with a mixture of water/ACN/TFA 
(14:80:6, v/v/v). Next, the digested sample was incubated with the 
washed beads for 30 min at room temperature, the beads were washed 
once with a mixture of water/ACN/TFA (14:80:6, v/v/v) and three 
times with a mixture of water/ACN/TFA (19:80:1, v/v/v). Phospho-
peptides were eluted from the beads by adding 80 μl 1% NH4OH three 
times. 60 μl 10 % formic acid (FA) was added to the combined eluate and 
the samples were dried completely in a speedvac vacuum concentrator. 
2.11.2. LC–MS/MS analysis 
LC–MS/MS analysis was performed at the VIB Proteomics Core. Pu-
rified peptides for shotgun analysis were re-dissolved in 20 μl solvent A 
and 2 μl of each sample was injected for LC–MS/MS analysis on an Ulti-
mate 3000 RSLCnano system (Thermo) in line connected to a Q Exactive 
mass spectrometer (Thermo). Trapping was performed at 10 μl/min for 4 
min in loading solvent A on a 10 mm μPAC™ trapping column (Phar-
maFluidics) with C18-endcapped stationary phase and the samples were 
loaded on a 50 cm long micro pillar array column (PharmaFluidics) with 
C18-endcapped functionality mounted in the Ultimate 3000’s column 
oven set at 35 ◦C. For proper ionization, a fused silica PicoTip emitter (10 
μm inner diameter, New Objective) was connected to the μPAC™ outlet 
union and a grounded connection was provided to this union. Peptides 
were eluted by a non-linear increase from 1 to 50 % MS solvent B (0.1 % 
FA in water/ACN (2:8, v/v)) over 159 min, first at a flow rate of 750 nl/ 
min, then at 300 nl/min, followed by a 5-minutes wash reaching 95 % MS 
solvent B and re-equilibration with MS solvent A (0.1 % FA in water). The 
mass spectrometer was operated in data-dependent, positive ionization 
mode, automatically switching between MS and MS/MS acquisition for 
the 5 most abundant peaks in a given MS spectrum. The source voltage 
was 2.9 kV, and the capillary temperature was 275 ◦C. One MS1 scan (m/z 
400 − 2,000, AGC target 3 × 106 ions, maximum ion injection time 80 
ms), acquired at a resolution of 70,000 (at 200 m/z), was followed by up 
to 5 tandem MS scans (resolution 17,500 at 200 m/z) of the most intense 
ions fulfilling predefined selection criteria (AGC target 5 × 104 ions, 
maximum ion injection time 80 ms, isolation window 2 Da, fixed first 
mass 140 m/z, spectrum data type: centroid, intensity threshold 1.3xE4, 
exclusion of unassigned, 1, 5–8, >8 positively charged precursors, pep-
tide match preferred, exclude isotopes on, dynamic exclusion time 12 s). 
The HCD collision energy was set to 25 % Normalized Collision Energy 
and the polydimethylcyclosiloxane background ion at 445.120025 Da 
was used for internal calibration (lock mass). 
Peptides resulting from phosphopeptide enrichment were re- 
dissolved in 20 μl solvent A and 10 μl was injected for LC–MS/MS 
analysis on an Ultimate 3000 RSLCnano system in-line connected to a Q 
Exactive HF mass spectrometer equipped with a Nanospray Flex Ion 
source (Thermo). Trapping was performed at 10 μl/min for 4 min in 
solvent A on a 20 mm trapping column (made in-house, 100 μm internal 
diameter (I.D.), 5 μm beads, C18 Reprosil-HD, Dr. Maisch, Germany) 
and the samples were loaded on a 50 cm long micro pillar array column 
(PharmaFluidics) with C18-endcapped functionality mounted in the 
Ultimate 3000’s column oven set at 35 ◦C. For proper ionization, a fused 
silica PicoTip emitter (10 μm inner diameter) (New Objective) was 
connected to the μPAC™ outlet union and a grounded connection was 
provided to this union. Peptides were eluted by a non-linear increase 
from 1 to 50 % MS solvent B (0.1 % FA in water/ACN (2:8, v/v)) over 
159 min, first at a flow rate of 750 nl/min, then at 300 nl/min, followed 
by a 5-minutes wash reaching 95 % MS solvent B and re-equilibration 
with MS solvent A (0.1 % FA in water). The mass spectrometer was 
operated in data-dependent, positive ionization mode, automatically 
switching between MS and MS/MS acquisition for the 5 most abundant 
peaks in a given MS spectrum. The source voltage was 2.6 kV, and the 
capillary temperature was 275 ◦C. One MS1 scan (m/z 400 − 2,000, AGC 
target 3 × 106 ions, maximum ion injection time 80 ms), acquired at a 
resolution of 70,000 (at 200 m/z), was followed by up to 5 tandem MS 
scans (resolution 17,500 at 200 m/z) of the most intense ions fulfilling 
predefined selection criteria (AGC target 5 × 104 ions, maximum ion 
injection time 80 ms, isolation window 2 Da, fixed first mass 140 m/z, 
spectrum data type: centroid, intensity threshold 1.3xE4, exclusion of 
unassigned, 1, 5–8, >8 positively charged precursors, peptide match 
preferred, exclude isotopes on, dynamic exclusion time 12 s). The HCD 
collision energy was set to 25 % Normalized Collision Energy and the 
polydimethylcyclosiloxane background ion at 445.120025 Da was used 
for internal calibration (lock mass). QCloud was used to control in-
strument longitudinal performance during the project [52]. 
2.11.3. Data processing 
Data processing was performed at the VIB Proteomics Core. Data 
analysis of the shotgun and phosphoproteomics data was performed 
with MaxQuant (version 1.6.10.43) using the Andromeda search engine 
with default search settings including a false discovery rate set at 1% on 
PSM, peptide and protein level. Spectra were searched against the 
human proteins in the UniProt Reference Proteome database (database 
release version of June 2019 containing 20,960 human protein se-
quences, (http://www.uniprot.org) supplemented with the sequences of 
AKT2 Nb8 and the EGFP Nb. The mass tolerance for precursor and 
fragment ions was set to 4.5 and 20 ppm, respectively, during the main 
search. Enzyme specificity was set as C-terminal to arginine and lysine, 
also allowing cleavage at proline bonds with a maximum of two missed 
cleavages. Variable modifications were set to oxidation of methionine 
residues, acetylation of protein N-termini and phosphorylation of serine, 
threonine or tyrosine residues, while carbamidomethylation of cysteine 
residues was set as fixed modification. Matching between runs was 
enabled with a matching time window of 0.7 min and an alignment time 
window of 20 min. Only proteins with at least one unique or razor 
peptide were retained leading to the identification of 3,805 proteins and 
9,999 phosphorylated sites. Proteins were quantified by the MaxLFQ 
algorithm integrated in the MaxQuant software. A minimum ratio count 
of two unique or razor peptides was required for quantification. 
2.11.4. Data analysis 
Further data analysis of the shotgun results was performed with the 
Perseus software (version 1.6.2.1) after loading the proteingroups file 
from MaxQuant. Reverse database hits, potential contaminants and 
proteins that were only identified by site were removed, LFQ intensities 
were log2 transformed and replicate samples were grouped. Proteins 
with less than three valid values in at least one group were removed and 
missing values were imputed from a normal distribution (width 0.3 and 
down shift 1.8) around the detection limit leading to a list of 2,509 
quantified proteins that was used for further data analysis. Then, a t-test 
was performed (FDR = 0.05 and s0 = 0) and significant hits were filtered 
for Log2LFQ(Nb8/EGFP Nb) difference of <-1 or >1 to compare differ-
ences in protein levels between Nb8- and EGFP Nb-expressing cells. A 
volcano plot was generated. 37 proteins were found to be significantly 
regulated. 
For the analysis of the phosphoproteome data, the phospho(STY) 
sites file was loaded in the Perseus software (version 1.6.2.1). Reverse 
hits and potential contaminants were removed, the site table was 
expanded and the intensity values were log2 transformed. Replicate 
samples were grouped, phosphosites with less than three valid values in 
at least one group were removed and missing values were imputed from 
a normal distribution (width 0.3 and down shift 1.8) around the 
detection limit leading to a list of 7,677 quantified phosphopeptides that 
was used for further data analysis. Then, a t-test was performed (FDR =
0.05 and s0 = 0) and significant hits were filtered localization proba-
bility ≥0.75 and for Log2LFQ(Nb8/EGFP Nb) difference of <-1 or >1 to 
compare Nb8- and EGFP Nb-expressing cells. A volcano plot was 
generated. 189 phosphopeptides were significantly regulated. 
The Panther classification system was used to determine statistical 
overrepresentation of GO-terms in the list of significantly regulated 
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proteins. The whole Homo sapiens gene set was used as reference list, a 
Fisher’s exact test with Bonferroni correction for multiple testing was 
used to determine significantly enriched (p < 0.05) terms. 
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the 
dataset identifier PDX020637 (login username: reviewer19716@ebi.ac. 
uk and password: iJKACkge). 
2.12. Detection of cyclin D1 expression levels 
MDA-MB-231 cell lines (parental, EGFP Nb, Nb5, Nb8 and Nb9) were 
seeded in 6-wellplates at 80,000 cells / well. Nb expression was induced 
by Dox (500 ng/mL). A control condition of untreated cells and cells 
treated with 5 μM Mk-2206 were also included. After 24 h incubation, 
cells were lysed using RIPA lysis buffer and 10 μg WCL was analysed 
through SDS-PAGE and western blotting. P-AKT2 S474 was detected 
using D3H2, Cyclin D1 using Ab16663, Vinculin by hVIN-1 and Nbs 
through their V5-tag. Vinculin was used as loading control. Signal in-
tensity was quantified using ImageJ and a Wilcoxon signed rank test 
(GraphPad Prism v5.00) was used to compare treated cells with control 
conditions. 
2.13. Cell cycle analysis 
180,000 cells were seeded in 25 cm2 culture flasks and treated with 
Dox (500 ng/mL) for 24 h. Cells were detached, fixed with ice cold 70 % 
ethanol for 30 min and permeabilized with 0.2 % Tween-20 and 0.2 % 
saponin in PBS. After blocking in 5 % (w/v) BSA and 0.2 % Tween-20 in 
PBS cells were incubated for 1 h at RT with 1 μg/mL anti-V5-AF645 
(Thermo Fisher Scientific, 451098). Cells were washed twice with PBS 
between incubation steps. Finally, the cells were incubated with 100 μg/ 
mL RNase A (Roche) for 5 min at RT and subsequently with 50 μg/mL 
Propidium Iodide (Sigma Aldrich, P4170). Samples were run on an At-
tune NxT Flow Cytometer (Invitrogen). The obtained data was analysed 
with FlowJo™ (v10). Samples were gated to exclude cellular debris and 
doublets. A one-way ANOVA with Tukey’s multiple comparison test 
(GrahPad Prism v5.00) was used to determine significant changes in the 
proportion of cells in each cell cycle phase. 
2.14. Detection of LC3B-II 
MDA-MB-231 cells (parental, EGFP Nb, Nb5, Nb8 or Nb9) were 
seeded in 6-wellplates at 100,000 cells/well. After ON incubation cells 
were treated (5 μM Mk-2206 for the parental cells and 500 ng/mL Dox 
for stable cell lines) and incubated for 24 h. untreated cells were 
included as a control, as well as cells which were, in addition to Mk-2206 
or Dox, also treated with 100 mM NH4Cl for 4 h. Cells were lysed using 
ice cold RIPA lysis buffer and a 25 μg sample was analysed by SDS-page 
and western blotting. The LC3B Ab (Cell Signaling Technology, 2775) 
detected both LC3B-I and LC3B-II. Actin (Abcam, Ab8229) was used as 
loading control, Nbs were detected using their V5-tag. Signal was 
quantified using ImageJ and a Wilcoxon signed rank test (GraphPad 
Prism v5.00) was used to detect significant differences between treated 
cells and control. 
2.15. Quantification of CD29 levels 
MDA-MB-231 cells expressing Nb8 or the EGFP Nb were seeded in 6- 
wellplates. Nb expression was induced by Dox (500 ng/mL) and cells 
were lysed immediately,after 24 h and 48 h using ice cold RIPA lysis 
buffer. A 10 μg sample was analysed by SDS-page and western blotting. 
CD29 was detected using P5D2 (Abcam, 24693) and Nbs using an anti- 
V5 Ab. GAPDH (Abcam, Ab8245) was used as loading control. Signal 
intensity was quantified using ImageJ and a one-way ANOVA with 
dunnett’s multiple comparison test (GraphPad v5.00) to analyse dif-
ferences between time points. 
3. Results 
3.1. The AKT2 Nbs are high-affinity interactors 
To further characterize the obtained nanobodies we determined 
detailed binding characteristics with AKT2 (stoichiometry, kon & koff) 
through Bio-layer Interferometry (Fig. 1A-C). The obtained binding 
Fig. 1. Bio-layer interferometry for AKT2 Nbs. 
A-C: association and dissociation curves for the interaction of AKT2 Nbs 5, 8 and 9 with FL-AKT2. Nbs with a C-terminal HA-His6-tag, obtained from an E. coli 
periplasmatic extract, were loaded onto biosensors coated with an anti-penta-His Ab. After measuring the background in the buffer, the tips were dipped into buffer 
solution containing AKT2 at various concentrations (association) and subsequently into a well containing only buffer for dissociation. The binding and release of 
AKT2 produced a shift in the interference pattern of reflected light, which was measured in real-time, resulting in the shown binding curves. D: SDS-PAGE and 
Western blot of human FL-AKT2 (UniProt P31751) which was produced as an intein fusion protein in BL21 E. coli and purified using the IMPACT™ system followed 
by anion-exchange chromatography. Column fractions 28–30 are shown. Purity was assessed by SDS-PAGE and Western blotting using an AKT2 specific Ab. The 
uncropped gel and blot are available in Supplementary Fig. S1. 
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curves, for all Nbs, were fit using a 1:1 binding kinetic model. X2 and R2 
values were < 3 and > 0.95, respectively, which indicated that this was a 
good fit. All AKT2 Nbs interacted with recombinantly produced AKT2 
with (sub)nanomolar affinity: Nb5 KD = 5.5 nM ± 64.9 pM, Nb8 KD =
118 nM ± 3.03 nM and Nb9 KD = 583 pM ± 13.8 pM. 
3.2. Modulation of AKT2 in cancer cells 
3.2.1. Generation of stable cell lines expressing the AKT2 Nbs as 
intrabodies 
Previous experiments indicated that AKT2 Nb5, 8 and 9 only interact 
with the AKT2 isoform [50]. Using these Nbs as intrabodies (Nbs 
expressed intracellularly) would allow us to study the function of AKT2 
without perturbing the other two isoforms. The AKT2 Nbs and EGFP Nb 
were subcloned into the lentiviral, tetracycin-inducible pLVX-Tight--
Puro expression vector and transduced into MDA-MB-231 human breast 
cancer cells. Stable MDA-MB-231 cell lines with doxycycline (Dox)--
inducible expression of the AKT2 Nbs or the EGFP Nb were generated 
(Fig. 2A). All nanobodies were successfully expressed in the stable cell 
lines. Co-immunoprecipitation (Co-IP) experiments to assess the 
intrabody-AKT2 interaction showed that all AKT2 Nbs were able to 
pull-down AKT2 (Fig. 2B). The EGFP Nb-expressing cell line was used as 
control. Using the same procedure, no AKT1 or AKT3 could be detected 
in a Co-IP experiment (Supplementary Fig. S2). 
3.2.2. Nb8 and Nb9 negatively regulate MDA-MB-231 cell viability or 
proliferation 
Several cellular processes regulated by AKT2 directly affect cell 
viability or metabolism. XTT and clonogenic assays were performed to 
determine whether the Nbs have a cytostatic/cytotoxic effect on MDA- 
MB-231 cells (Fig. 3A and Supplementary Fig. S4). Both the parental 
cell line and the stable cell line expressing the EGFP Nb were used as 
controls. The effect of Nb expression was measured for up to 72 h at 
intervals of 24 h. A 2-way ANOVA showed that there was significant 
interaction (F(8,44) ¼ 5.78, p ≤ 0.0001) between Nb and expression 
time (a time-dependent effect of Nb expression on OD475 of the formazan 
dye). Simple effects analysis by one-way ANOVA showed, that for all 
measured time points (24, 48 and 72 h), cells expressing either Nb8 or 
Nb9 had significantly (p < 0.05) lower mean OD475 when compared to 
the parental cell line and EGFP Nb- or Nb5-expressing cell lines. Cells 
expressing Nb5 did not exhibit a significant (p > 0.05) shift in mean 
OD475 compared to the controls indicating that, at any of the measured 
time points, Nb5 did not affect viability or cell division. Both Nb8 and 
Nb9 had a time-dependent effect on OD475 with significantly lower 
values after 48 h compared to 24 h. However, the effect of these Nbs 
appeared to reach a maximum after 48 h. Additionally, Nb8 and Nb9 
elicited a comparable effect on the cells as their mean OD475 was not 
significantly different at any time point. These results indicate that the 
interaction of Nb8 or Nb9 with AKT2 negatively affects its function, 
Fig. 2. AKT2 Nbs as intrabodies in MDA-MB-231 cells. 
A: Stable and inducible expression of the EGFP Nb and AKT2 Nbs in MDA-MB-231 cells. Representative epifluorescence images of stable MDA-MB-231 cells with Dox- 
inducible Nb expression. Nb expression was induced with 500 ng/mL Dox (þDox), uninduced cells (-Dox) were included to assess leakage expression. Merged images 
are shown, nuclei were visualized by DAPI (blue) and Nbs with an anti-V5 Ab (green). Scale bar, 10 μm. B: Co-IP of endogenous AKT2 from stable MDA-MB-231 cells 
with V5-tagged intrabodies using anti-V5 agarose. Nb expression was induced with 500 ng/mL Dox. WCL= whole cell lysate, C= control using the EGFP Nb- 
expressing stable cell line. HC= Heavy-Chain, LC= Light-Chain. All Nbs were expressed in the stable cell lines and only the AKT2 Nbs pulled-down AKT2. AKT2 
was detected using an isoform-specific Ab, Nbs were detected through their V5-tag. Co-IPs for AKT1, AKT3 and uncropped blots are available in Supplemen-
tary Fig. S3. 
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possibly through different mechanisms as they bind separate epitopes 
[50]. Although it has been shown that pan-AKT inhibition induces 
apoptosis, our results indicated that this was not the case for Nb8 or Nb9 
(Fig. 3B) [53]. No reduction in full length caspase-3 nor the presence of 
cleaved Caspase-3 could be detected in cells expressing Nb8 or Nb9 for 
up to 72 h whereas staurosporine, the positive control, induced both. 
Considering that caspase-3 is activated at the end of both intrinsic and 
extrinsic apoptotic pathways, these results strongly argue against the 
involvement of this cell death mechanism in the effects observed in the 
XTT-assay. Additionally, we did not observe the typical changes in cell 
shape nor detachment of cells from substrate, signs of apoptosis, in 
Nb-expressing cells. This was however the case in staurosporine-treated 
cells. 
3.2.3. Nb8 affects AKT2 HM phosphorylation in IGF-1 stimulated cells 
Epitope mapping experiments showed that Nb8 interacts with the 
AKT2 HM and Nb9 with the pleckstrin homology (PH) domain [50]. 
Both Nbs can potentially interfere with AKT2 activation: Nb8 by 
shielding the modification site in the HM and Nb9 by interfering with 
the PH-phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3) 
interaction [6,7,50]. The effect of the AKT2 Nbs on phosphorylation of 
the AKT2 HM was determined through Western blotting (Fig. 4A). In 
cells expressing Nb8 we observed a clear and significant reduction 
(one-way ANOVA, p < 0.0001) in pAKT2 S474 levels after 1, 5 and 30 
min IGF-1 stimulation but not after 15 min IGF-1 stimulation (Fig. 4B). 
Such an effect was not observed in Nb5-, Nb9- or EGFP Nb-expressing 
cells. Total AKT2 levels were unchanged at any of the measured time 
points (one-way ANOVA, p < 0.05). 
3.2.4. Nb8 expression resulted in significant changes in the (phospho) 
proteome 
The AKT kinases are part of a large signalling cascade involving 
downstream kinases and transcription factors. AKT2’s phosphorylation 
status determines its catalytic activity and, possibly, which substrates 
can be phosphorylated by the kinase [54,55]. To obtain a comprehen-
sive view of Nb8’s effects on AKT2 signalling, the proteome and phos-
phoproteome of MDA-MB-231 cells expressing Nb8 or the EGFP Nb were 
compared. Using a label-free approach we were able to reliably quantify 
2,509 proteins and 7,677 phosphosites on 1,998 proteins. A student’s 
t-test and filtering by difference in intensity resulted in the identification 
of 151 down- and 38 up-regulated phosphosites (Fig. 5A). As changes in 
regulation of a protein modification (phosphosite) can reflect changes in 
regulation of the whole protein, protein expression levels in the same 
samples were quantified (shotgun proteome (SG) analysis) prior to 
phosphoprotein enrichment. Fold change values of phosphosites, for 
which the whole protein could be quantified, were normalized. This was 
possible for 74 phosphosites (39 % of all identified phosphosites). The 
SG proteome analysis indentified 37 differentially regulated proteins (20 
Fig. 4. Nb8 expression attenuates IGF-1 response in MDA-MB-231 cells. 
A: Western blot detection of HM-phosphorylated AKT2 (pAKT2 S474). 1= cells grown in standard growth medium, 2¼ 48 h serum starved and IGF-1 (5 ng/mL) 
stimulated cells without Nb8 expression and 3¼ 48 h serum starved and IGF-1 (5 ng/mL) stimulated cells with Nb8 expression (500 ng/mL Dox). Vinculin was used 
as loading control and Nb8 was detected through its V5-tag. AKT2 and pAKT2 S474 were detected using isoform-specific Abs. Uncropped blots are available in 
Supplementary Fig. S6. B: ImageJ quantification of AKT2 and pAKT2 S474 levels. Values were normalized for vinculin. The fold change of AKT2 and pAKT2 S474 
levels between Nb8-expressing cells and uninduced cells was calculated. A one-way ANOVA indicated there was a significant reduction in pAKT2 S474 levels for Nb8- 
expressing cells after 1, 5 and 30 min IGF-1 stimulation. Total AKT2 levels did not significantly differ for any time point. 
Fig. 3. Cytotoxic and cytostatic effect of AKT2 intrabodies on MDA-MB-231 cells. 
A: XTT-assay of the Parental (PAR) and stable MDA-MB-231 cell lines expressing the EGFP Nb or AKT2 Nb5, 8 and 9. Both the Parental and EGFP Nb-expressing cell 
lines were used as negative control. Values shown are the mean and SD of OD475 values normalized for the EGFP Nb for three repeated experiments. A one-way 
ANOVA with Tukey’s multiple comparison test was used to compare mean OD475 values. * p < 0.05, ** p < 0.01, ***p < .001. Full statistical analysis can be 
found in Supplementary Table S1. B: Western blot detection of caspase-3 processing in AKT2 Nb8- or Nb9-expressing MDA-MB-231 cells. 1= untreated, 2=
Staurosporine (10 μM), 3 = 24 h 500 ng/mL Dox, 4= 48 h 500 ng/mL Dox, 5= 72 h 500 ng/mL Dox. The 17 and 19 kDa fragments of caspase-3 could not be detected 
in cells expressing Nb8 or Nb9, indicating that the observed reduction in cell count was not a consequence of apoptosis. Vinculin was used as loading control. 
Uncropped blots are available as Supplementary Fig. S5. 
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down- and 17 up-regulated proteins) in Nb8-expressing cells (Fig. 5B). 
The full list of differentially regulated phosphosites and proteins can be 
found in Supplementary Proteomics Data. Both PCA analysis of all 
quantified phosphosites or proteins and hierarchical clustering of 
differentially regulated proteins/phosphosites clearly grouped the 
replicate samples by ‘treatment’ i.e. Nb8 or EGFP Nb expression (Sup-
plementary Fig. S7). 
AKT2 protein expression was not differentially regulated between 
EGFP Nb- and Nb8-expressing cells, but no phosphorylated AKT2 pep-
tides were identified. For both AKT1 and AKT3, phosphopeptides were 
Fig. 5. Differential (phospho)proteome analysis of Nb8- vs EGFP Nb-expressing cells. 
Relative phosphopeptide (A) or protein (B) intensities (Log2LFQ(Nb8/EGFP Nb)) are plotted versus statistical significance (-Log10(P value, two-sided student’s t- 
test)). Quantified peptides were filtered by significance (permutation-based false discovery rate calculation, FDR = 0.05 S0 = 0) and a difference ≥1 or ≤-1. Hits 
which were up-regulated in Nb8-expressing cells are indicated in red, down-regulated hits in blue. C: A selection of enriched GO terms with fold change and p-value 
are plotted, divided into three categories: ‘cellular component’, ‘biological process’ and ‘molecular function’. 
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identified, none of which met the criteria for different regulation. The 
site identified for AKT3 (S472) is the HM site, corresponding to S474 in 
AKT2. A total of 20 known AKT substrates were quantified, none of these 
were differentially regulated between Nb8- and EGFP Nb-expressing 
cells (Supplementary Table S2). These sites include BAD S99, GSK3β 
S9 and, a known AKT1 substrate, PALLADIN S1118. A NetPhos motif 
search identified three potential AKT substrate sites: TRA2A (T88), 
SRRM1 (S551) and IRS1 (S270), all of which were down-regulated in 
Nb8-expressing cells [56]. 
To identify the cellular processes influenced by Nb8 expression, all 
differentially regulated proteins (phosphorylation and expression) were 
subjected to PANTHER Gene Ontology (GO) term enrichment and KEGG 
pathway mapping [57]. A selection of enriched terms is shown in 
Fig. 5C. Fold enrichment and P-values for all significantly enriched GO 
terms can be found in the supplementary data. For cellular component, 
both ‘nucleoplasm’ and ‘cytosol’ were enriched while ‘integral compo-
nent of membrane’ was underrepresented. This could indicate that our 
analysis did not equally cover the whole proteome. Interestingly, given 
the results from the XTT and clonogenic assays, ‘mitotic cell cycle’ was 
an enriched biological process term and five proteins were mapped to 
the KEGG ‘cell cycle’ pathway. AKT2 inactivation has been linked to 
autophagy. Proteins involved in autophagy, mitophagy and phagophore 
assembly site were overrepresented in the significantly regulated pro-
teins. Additionally, seven proteins were mapped to the ‘KEGG auto-
phagy – animal’ pathway [23,58]. Several terms pertaining to the 
cytoskeleton and cell motility were enriched including, but not limited 
to, stress fiber, basement membrane, cell-cell adherens junction, focal 
adhesion and cytoskeleton. Furthermore, mapping the protein list to 
KEGG pathways identified seven hits to be part of the ‘focal adhesion’ 
pathway and five hits were mapped to the ‘actin cytoskeleton’ pathway. 
These results prompted us to investigate the effects of Nb8 on the cell 
cycle, autophagy and focal adhesions in more detail. 
3.2.5. Nb8 interference with AKT2 results in a G0/G1 cell cycle arrest 
The AKT family was previously established as a regulator of the cell 
cycle [59]. In total, the GO enrichment and KEGG pathway mapping 
yielded 26 proteins (Fig. 5C, Supplementary Table S3) involved in 
various stages of the mitotic cell cycle or regulation of DNA metabolic 
processes. Retinoblastoma-associated protein (RB1), a tumour suppres-
sor and regulator of the cell cycle, was hypophosphorylated on multiple 
sites. These phosphosites were not down-regulated to the same extent 
and RB1 expression was not significantly (p > 0.05) down-regulated in 
Nb8-expressing cells. With the exception of S37, the identified RB1 
phosphosites are regulated by Cyclin D1-CDK4/6 complexes or Cyclin 
A/E-CDK2 complexes [60]. 
The localization and degradation of Cyclin D1 is regulated by 
phosphorylation on T286, downstream of AKT and AKT also regulates 
Cyclin D1 activity through CDKN1A and CDKN1B [61–63]. Immuno-
fluorescence (IF) and Western blotting were used to determine the effect 
of Nb8 expression on Cyclin D1. IF experiments showed that Cyclin D1 
was enriched in the nucleus (Supplementary Fig. S8) (co-localization 
with DAPI according to Mander’s Colocalization Coefficient quantified 
using ImageJ) [64]. This was still the case in MK-2206 (pan-AKT 
inhibitor)-treated cells and EGFP Nb- or Nb5-expressing cells (Fig. 6A). 
In cells expressing Nb8, the nuclear enrichment of Cyclin D1 was lost as 
these cells had a significantly lower overlap between DAPI and Cyclin 
D1 (one-way ANOVA, p < 0.001) (Fig. 6B). No (phospho)peptides for 
Cyclin D1 were found in the proteomics analyses. Western blotting was 
used to determine changes in Cyclin D1 protein expression levels. 
Nb8-expressing cells showed a significant (Wilcoxon signed rank test, p 
< 0.001) reduction in Cyclin D1 levels when compared to the 
un-induced control (Fig. 6C, D). Again, we found that MK-2206 treat-
ment had no effect on Cyclin D1 even though it strongly reduced AKT2 
S474 phosphorylation. A one-way ANOVA with Dunnett’s test indicated 
that there were no significant differences in Cyclin D1 levels between the 
EGFP Nb-, Nb5- and Nb9-expressing or MK-2206-treated cells. In addi-
tion, we found that CDK2 levels were also significantly down-regulated 
in Nb8-expressing cells (Wilcoxon signed rank test, p < 0.05). A cell 
cycle analysis showed that, compared to the EGFP Nb-expressing cells, 
the Nb8-expressing cell line had a significantly (one-way ANOVA with 
Tukey’s multiple comparison test, p < 0.001) higher proportion of cells 
in the G0/G1 phase (þ19.36 ±3.43 %) at the expense of cells in both 
the S (-10.22 ± 1.77 %) and G2 phase (-8.77 ± 2.77 %) (Fig. 6E). The 
cell cycle profile of Nb5- and Nb9-expressing cells was similar to that of 
EGFP Nb-expressing cells. With the exception of the G2 phase of cells 
expressing Nb9, which showed a very small (-3.08 ± 3.06 %) but sig-
nificant (p < 0.05) decrease, there were no significant differences in 
population for any cell cycle phase. Full data for the one-way ANOVA 
with Tukey’s post-test can be found in Supplementary Fig. S9. 
Although the experiments above focused on signalling events 
downstream of Cyclin D1-CDK4/6 complexes, CDK2 and the cell cycle 
entry of MDA-MB-231 cells, there were indications of reduced activity of 
other cyclin-dependent kinases (CDKs) and reduced phosphorylation of 
proteins which function in later stages of the cell cycle (Supplementary 
Table S3). NIFK, an interaction partner of Ki-67, phosphorylation was 
down-regulated on T234 and T238, substrate sites for GSK3α/β and 
CDK1, respectively. Although this infers reduced GSK3α/β activity, 
T234 can only be phosphorylated after CDK1 has phosphorylated T238 
[65]. Reduced CDK1 activity would thus result in a reduction of phos-
phorylation for both these sites. Phosphorylation of both sites is required 
for the NIFK-Ki-67 interaction. Both proteins are recruited to the chro-
mosome periphery during mitosis [66]. Ki-67, a biomarker for prolif-
erating cells, phosphorylation on S1937, S2223 and T2231 were also 
reduced. TPX2, a protein involved in cell cycle progression, phosphor-
ylation was down-regulated on S738, another CDK1 substrate site and 
RRM2, which regulates the synthesis of DNA precursors, was 
down-regulated on S20 which is a CDK2 substrate site. 
Taken together, our other results show that Nb8 expression affected 
cell cycle progression through inhibition of the AKT2/CyclinD1-CDK2/ 
RB1 signalling cascade. The final result was a reduction in RB1 phos-
phorylation on several CDK-dependent sites allowing this protein to 
exert its tumour suppressive function, i.e. Nb8-expressing cells failed to 
enter the S-phase. 
Fig. 6. Nb8 expression affected cell cycle progression through Cyclin D1 regulation. 
A: Representative epifluorescence images of MDA-MB-231 cells treated with 5 μM MK-2206 or stably expressing AKT2 Nb5, Nb8 or the EGFP Nb (500 ng/mL Dox). 
The Nbs were distributed equally throughout the cells (red). In cells treated with MK-2206 or expressing Nb5 or the EGFP Nb, the signal for Cyclin D1 (green) 
coincided with the signal for DAPI (blue), indicating a nuclear enrichment of Cyclin D1. In Nb8-expressing cells this nuclear staining pattern was lost. Scale bar, 10 
μm. B: Plotted mean and 95 % CI of Manders’ Colocalization Coefficient after Costes thresholding (tM1) for DAPI and Cyclin D1 for at least 85 cells. A one-way 
ANOVA with Tukey’s multiple comparison test indicated tM1 for Nb8-expressing cells was significantly (p < 0.0001) lower compared to tM1 of the EGFP Nb- or 
Nb5-expressing cells and MK-2206-treated cells. Colocalization coefficients for all other treatments (MK-2206, EGFP Nb and Nb5) were not significantly different. C: 
Western Blot detection of Vinculin (loading control), AKT2 phosphorylated on S474 (pAKT2 S474), Cyclin D1, CDK2 and Nb8. 1¼ untreated cells, 2¼ Dox-treated 
(500 ng/mL) and 3¼ MK-2206-treated (5 μM) MDA-MB-231 cells. Representative for at least six repeated experiments. D: Quantification of Cyclin D1 and CDK2 
using ImageJ. Values were normalized for vinculin. The fold change for Dox-treated versus untreated cells is plotted. All data points are shown with their mean 
(dashed line) and a 95 % CI (Whiskers). * p < 0.05 and *** p < 0.001, Wilcoxon signed rank test. Repeats are available in Supplementary Fig. S10. E: Cell cycle 
phase distribution of Nb-expressing MDA-MB-231 cells. Cells were gated to exclude debris, doublets and to include Nb-expressing cells. Values shown are the mean 
and SD of at least 3 repeated experiments. The proportion of cells in the G0/G1-, S- and G2-phase is shown as a percentage. Note that the y-axis has a break between 
10 % and 60 %. 
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3.2.6. Nb8 activates autophagy 
Previous studies indicated that ablation of AKT2 induces autophagy 
[23]. Autophagy (and mitophagy) were enriched biological processes 
identified in our proteomics analysis along with the cellular component 
‘phagophore assembly site’. Pooling the hits from these GO keywords 
yielded 12 proteins with 14 differentially regulated phosphosites and 
four proteins with significant changes in expression levels (Fig. 5C, 
Supplementary Table S4). One of those proteins, Transcription factor EB 
(TFEB), controls expression of autophagy-related and lysosomal genes, 
among which are MAP1LC3B (LC3B) and ATG9A. TFEB is phosphory-
lated by mTORC1 on S122 and S142, resulting in the cytoplasmatic 
retention and inactivation of TFEB [67,68]. Both of these sites were 
down-regulated in Nb8-expressing cells along with S109, S114 and 
S138, the former two of which have also been shown to regulate TFEB 
localization. Additionally, RBC1CC1/FIP200, an integral part of the ULK 
complex, phosphorylation on S222 was up-regulated as were phos-
phorylation sites of MAP1B (S541, S1785, T1788 and S2211), while 
both ATG2B (S497) and ATG9A (S656) phosphorylation were 
down-regulated. The effect of these PTMs for RB1CC1, MAP1B, ATG2B 
and ATG9A is unknown, but these proteins are involved in autophago-
some formation, ATG2B and ATG9A in the early stages and 
RB1CC1/FIP200 in both early and late stages. Phosphorylated MAP1B 
Fig. 7. Nb8 induced autophagy. 
A: Western blot detection of LC3B-II. 1¼ untreated control, 2¼ MK-2206 (5 μM) or Dox (500 ng/mL) for 24 h and 3¼ MK-2206 or Dox (24 h) with NH4Cl (10 mM) 
added 4 h prior to cell lysis. Actin was used as loading control. The LC3B Ab detected both LC3B-I and LC3B-II. Nbs were detected through their V5-tag. B: ImageJ 
quantification of signal intensity. Values were normalized for the loading control (Actin) and experimental control (uninduced cells). All data points, their mean 
(dashed line) and a 95 % CI (whiskers) are shown. Both MK-2206-treated and Nb8-expressing cells showed a significant (*p < 0.05, Wilcoxon signed rank test) fold 
change increase in LC3B-II levels. C: Further increase in LC3B-II levels in NH4Cl-treated cells, indicating that an up-regulation of autophagy rather than inhibition of 
autophagic flux lies at the base of LC3B-II increase in MK-2206-treated and Nb8-expressing cells. Repeats are available as Supplementary Fig. S11. D: representative 
confocal images of MDA-MB-231 cells. Cells expressing Nb8 contained significantly more autophagosomes (as green dots, Cyto-ID). Mitochondria were stained using 
Mitotracker® Orange CMTMRos (red). Autophagosomes were located near the mitochondrial network in both Nb8-expressing and un-induced cells. Scale bar, 20 μm. 
E: Average amount (mean and 95 % CI) of autophagic vesicles per cell from at least 200 cells spread over three repeated experiments. Nb8-expressing cells had 
significantly (*** p < 0.0001) more autophagic vesicles per cell. 
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Fig. 8. Nb8 reduced the number of Focal Adhesions present in MDA-MB-231 cells. 
A: representative confocal images of MDA-MB-231 cells. Vinculin was used as a marker for Focal adhesions, actin filaments and Nbs were visualised using fluorescent 
phalloidin and an anti-V5 Ab, respectively. Focal adhesions are visible as green vinculin streaks at the ends of actin filaments. Nb8-expressing cells contained both 
less vinculin streaks and fewer structured actin filaments when compared to the control conditions. Vinculin image insets are after background subtraction and 
thresholding [51]. Scale bar, 20 μm. B: ImageJ quantification of FAs for at least 100 cells. ** p < 0.01, ***p < 0.001. C: Western blot detection of CD29 in 
MDA-MB-231 cells expressing the EGFP Nb-(control) or Nb8. Nb expression was induced by 500 ng/mL Dox for up to 48 h. GAPDH was used as loading control, the 
Nbs were detected through their V5-tag. D: ImageJ quantification of signal intensity for CD29, normalized for GAPDH. Repeats are available as Supplementary 
Fig. S12. A one-way ANOVA with dunnett’s multiple comparison test showed that, after 48 h of Nb8 expression, CD29 levels were significantly reduced (p <0.05). 
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interacts with LC3B and links autophagosomes to microtubuli [69,70]. 
To determine whether these changes induced autophagy in Nb8- 
expressing cells we analysed the levels of LC3B-II. The precursor pro-
tein LC3B is cleaved to form LC3B-I which, on induction of autophagy, is 
lipidated (phosphatidylethanolamine conjugation) to LC3B-II. This 
lipidated form migrates faster in SDS-PAGE and can be used as a marker 
for autophagy (Fig. 7A) [71]. LC3B-II levels were significantly 
up-regulated in Nb8-expressing cells and MK-2206-treated cells (p < 
0.05, Wilcoxon signed rank test) when compared to the un-induced or 
untreated cells (Fig. 7B). The fold change in LC3B-II levels (normalized 
for their respective control) of Nb8-expressing cells or MK-2206-treated 
cells was not significantly different (p ¼ 0.84). An additional control, 
where NH4Cl is added to the medium of treated cells, was included to 
ensure LC3B-II up-regulation was due to increased autophagy and not 
inhibition of autophagic flux (downstream processing of autophagic 
cargo). NH4Cl prevents lysosomal acidification and the further increase 
of LC3B-II in doubly-treated (Dox + NH4Cl or MK-2206+NH4Cl) cells 
indicated that MK-2206-treatment or Nb8 expression did not block 
autophagic flux (Fig. 7C). The increased presence of autophagosomes in 
Nb8-expressing cells was confirmed though confocal microscopy using 
the Cyto-ID® dye (Fig. 7D). Mitochondria were stained using Mito-
Tracker® Orange CMTMRos and Nb8 was visualized through its V5-tag. 
The average amount of autophagic vesicles per cell was determined 
through ImageJ quantification. A Mann Whitney test indicated that 
Nb8-expressing cells contained significantly more autophagic vesicles (p 
< 0.0001) (Fig. 7E). 
Nb8 expression affected the phosphorylation status and expression 
levels of several proteins involved in autophagy. The observed LC3B-II 
upregulation and the higher amount of autophagic vesicles clearly 
shows the activation of autophagy as a result of Nb8 expression. 
3.2.7. Nb8 reduces focal adhesion count and CD29 expression 
In breast cancer cells, AKT1 and AKT2 have opposing effects on cell 
migration and metastasis, AKT1 activity reduces, while AKT2 enhances 
these processes. Our data indicated that Nb8 expression changes phos-
phorylation and/or expression levels of multiple proteins involved in 
cell adhesion and motility (Fig. 5C, Supplementary Table S5). Cell 
motility requires the dynamic remodeling of the cytoskeleton, including 
actin stress fibers and focal adhesions [72]. Focal adhesions (FA) are 
large protein complexes that link the extracellular matrix to the actin 
cytoskeleton through transmembrane integrins. In total, 17 and 7 
differentially regulated proteins were quantified that localize to FAs and 
stress fibers, respectively. 
The effect of these changes in protein expression and phosphoryla-
tion on FAs in MDA-MB-231 cells was determined through IF, using 
Vinculin as a marker for FAs and labelled phalloidin to visualize F-actin 
(Fig. 8A) [73]. FAs were quantified using ImageJ, the data are repre-
sentative for three repeated experiments with at least 100 cells for each 
treatment. A one-way ANOVA (with Dunnett’s multiple comparison 
test) indicated that cells expressing Nb8 had significantly fewer FAs (p < 
0.01 for EGFP Nb vs Nb8 and p < 0.001 for untreated and 
MK-2206-treated cells vs Nb8) (Fig. 8B). Peptides from Vinculin were 
identified in the SG proteomics analysis. LFQ indicated that Vinculin 
expression levels were unchanged for Nb8- vs EGFP Nb-expressing cells, 
suggesting that Vinculin is displaced from FAs. Additionally, 
Nb8-expressing cells contained fewer structured actin filaments. 
The expression of Integrin β1 (CD29), an integral part of FAs, is up- 
regulated by AKT2 and promotes breast cancer cell migration [20,33]. 
WB detection of CD29 showed CD29 levels were reduced in 
MDA-MB-231 cells after 48 h of Nb8 expression (Fig. 8C) (one-way 
ANOVA with Dunnett’s multiple comparison test, p < 0.05) (Fig. 8D). 
For the EGFP Nb-expressing cells no significant differences in CD29 
levels were found for any time point. 
4. Discussion 
In a previous study, we obtained and characterised three AKT2 
specific Nbs (Nb5, Nb8 and Nb9) which interact with the catalytic, HM 
and PH domain of AKT2, respectively [50]. Nbs can knock out specific 
protein functions without reducing protein expression levels [42–46,48, 
49,74]. This makes Nbs complementary tools to RNAi for studying 
protein function. However, a function-blocking Nb seems to be a better 
indicator of the effects of a conventional inhibitor and such Nbs (or their 
therapeutic epitope) can be used in the discovery or design of new in-
hibitors. Here, we present high-affinity AKT2-interactors that can be 
used in living cells. Through lentiviral transduction, the AKT2 Nbs were 
stably integrated into the genome of MDA-MB-231 cells and can 
pull-down endogenous AKT2. 
Nb9 has been shown to interfere with the interaction of the AKT2 PH- 
domain with PtdIns(3,4,5)P3 which, in theory, could affect AKT2 acti-
vation. However, despite the results from cell-free experiments, we did 
not observe a reduction in AKT2 HM phosphorylation in IGF-1 stimu-
lated cells expressing Nb9. The cell-free experiments did use a high 
molar excess of Nb9 over PH-domain. Nb9 has a higher affinity for the 
AKT2 PH-domain when compared to PtdIns(3,4,5)P3 (583 pM vs 590 
nM), but perhaps Nb9 expression levels were too low to overcome the 
sudden spike in local PtdIns(3,4,5)P3 concentration [75,76]. 
We found that Nb8 expression reduces phosphorylation of AKT2’s 
HM (S474) in IGF-1-stimulated cells. As Nb8 binds the HM and reduces, 
but not abolishes, phosphorylation of that domain it is likely that Nb8 
does not completely inhibit AKT2 function. Phosphorylation of the AKT 
HM has been shown to ‘fine tune’ AKT signalling, a reduction in phos-
phorylation of this site only affects a subpopulation of AKT substrates 
[35,54,55]. Nb8’s effect is not necessarily limited to reducing the cat-
alytic activity of AKT2. The interaction of Nb8 with the AKT2 HM could 
block ‘structural’ AKT2 functions. It could restrict access to specific 
AKT2 substrates or interfere with the interaction of AKT2-regulating 
proteins [44–46,49,74,77]. A phosphoproteome analysis reliably 
quantified 7,677 phosphosites, 189 of which were differentially regu-
lated between Nb8- and EGFP Nb-expressing cells. The shotgun prote-
ome analysis of the same samples quantified 2,509 proteins, 37 of these 
had significant changes in expression levels. The AKT3 HM phosphosite 
(S472) was quantified but not down-regulated in Nb8-expressing cells, 
which was expected as Nb8 does not interact with this isoform. The 
corresponding phosphosites for AKT1 and AKT2 were not quantified, 
nor was the phosphosite in the catalytic domain identified for any iso-
form. That several AKT substrate sites were quantified but not differ-
entially regulated indicates that these are either not AKT2-specific 
substrates or that their phosphorylation is not affected by a reduction of 
AKT2 HM phosphorylation. The phosphorylation status of T309 and 
S474 (residues for AKT2) has been suggested to determine substrate 
accessibility. Singly phosphorylated AKT at T309 would retain most of 
its functions, while doubly phosphorylated AKT (T309 and S474) adds 
additional substrates to its repertoire [54,55]. It remains to be seen 
whether this additional level in AKT regulation is also isoform-specific 
[12,35,54]. That no known AKT substrates were differentially regu-
lated also means that we were unable to find a direct link between AKT2 
and the differentially regulated phosphosites or proteins based on pre-
viously identified AKT substrates (PhosphoSitePlus). That the novel 
potential AKT substrates identified by a NetPhos sequence motif search 
were all down-regulated could indicate these are regulated by AKT2 and 
that they are affected by Nb8. 
BAD S99 is an example of an AKT substrate site that is unaffected by 
Nb8 expression. This is in line with our observation that Nb8 did not 
induce apoptosis, as shown by the lack of caspase-3 processing. This 
shows that AKT2 does not play a dominant role in the regulation of 
apoptosis in the breast cancer model used here. However, the roles of the 
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AKT isoforms in regulating apoptosis are most likely context-dependent. 
There are reported cases where knockdown of a single isoform was 
sufficient to induce apoptosis, but also where a combined knockdown of 
all isoforms was required to obtain a similar effect [2,30]. 
The AKT kinases are part of a large network that includes multiple 
kinases downstream of AKT [5]. We expected that the majority of the 
identified phosphosites would be indirectly regulated by AKT2. A Fisher 
exact test on substrate motifs for differentially regulated phosphosites 
showed consensus phosphorylation sites for CHK1, CAMK2, CAMK4, 
PKA and PKC were enriched. The AKT pathway also includes several 
transcription factors, 17 differentially regulated proteins have ‘tran-
scription regulation’ as UniProtKB keyword (Appendix ASupplementary 
Proteomics Data). Proteins of which the expression levels were signifi-
cantly altered add another layer of information to the effect of AKT2 
modulation by Nb8. 
GO term analysis and KEGG pathway mapping linked the differen-
tially regulated proteins (both phosphorylation and expression levels) to 
specific functions regulated by AKT2. Indeed, the vast majority of our 
protein hits are involved in processes known to be regulated by the AKT 
family [20,21,23,32,39,58,78]. Our results implicate AKT2 as the 
dominant isoform in cell cycle regulation. Phosphorylation levels of 
GSK3β, an AKT substrate that phosphorylates Cyclin D1 on T286 
inducing nuclear export, were unchanged. This indicates that GSK3β is 
not responsible for the reduction in Cyclin D1 expression levels which is 
in line with results from a study using AKT2 siRNA [23]. There are other 
kinases downstream of AKT, such as DYRK1B and IKKA, which can also 
phosphorylate this site [79,80]. Additionally, this effect could also be 
achieved by the inhibition of Cyclin D1-CDK4 complexes by CDKN1A or 
CDKN1B, both direct AKT substrates. CDKN1B upregulation has been 
observed in MDA-MB-231 cells with AKT2 down-regulation through 
siRNA [23,61]. The downregulation of Cyclin D1 and CDK2 accounts for 
the hypophosphorylation of seven out of eight detected RB1 phospho-
sites. These changes enable RB1 to exert its tumour suppressive func-
tions. That not all phosphosites were down-regulated to the same extent 
suggests that there may be other upstream elements involved in RB1 
regulation that are also affected by Nb8. Ten RB1 transcription targets 
that play a role in the cell cycle were quantified by shotgun proteomics. 
Only three (MCM6, RRM1 and CDK1) were significantly 
down-regulated, but the fold change was too low to be considered bio-
logically relevant [60]. Treating cells with MK-2206, a pan-AKT inhib-
itor, did not reduce Cyclin D1 or CDK2 levels. Another study has shown 
that MK-2206 treatment does not affect cell cycle progression in 
MDA-MB-231 cells [53]. Our results show this cell type is sensitive to 
AKT2 inhibition, resulting in a G0/G1 cell cycle arrest. This raises the 
question why AKT2 inhibition affects cell cycle progression, but full 
inhibition of the AKT family does not. Both AKT1 and AKT2 have been 
shown to regulate Cyclin D1 expression levels in MDA-MB-231 cells, 
which makes it unlikely that regulation of this process is AKT2-specific 
[23]. It is possible that complete inhibition of the AKT family triggers 
feedback mechanisms which are not activated by a reduction in AKT2 
activity alone [81,82]. 
Contrary to the effects on cell cycle progression, both Nb8 and MK- 
2206 had equal effects on induction of autophagy in MDA-MB-231 
cells, specifically LC3B-II up-regulation. This indicates that neither 
AKT1 nor AKT3 plays a significant role in this process as inhibition of 
these kinases along with AKT2 (in MK-2206-treated cells) did not have 
an additive effect on LC3B-II levels. Although this was not observed 
directly, the reduced phosphorylation of TFEB (and EEF2K) sites sug-
gests reduced mTORC1 activity, the main regulator of autophagy 
downstream of AKT. This is supported by the reduced RPS6KA1 S363 
phosphorylation, an upstream activator of mTORC1. In addition to this, 
we observed increased phosphorylation of RB1CC1/FIP200 and MAP1B, 
and reduced phosphorylation of ATG2B and ATG9A. We suggest these 
modifications play a role in autophagy regulation, although how these 
are linked to AKT2 remains to be elucidated. Autophagy in cancer is a 
double-edged sword as it can promote cell survival or cell death [83]. 
The uncontrolled autophagy induced by Nb8 can lead to cell death and 
contribute to the effect on cell viability/proliferation. Other studies have 
shown that AKT2 inhibition leads to targeted degradation of mito-
chondria by autophagy (mitophagy) [23]. However, we found that 
autophagosomes stained by Cyto-ID™ were localized to the mitochon-
drial networks regardless of Nb8 expression (although these were much 
fewer in number in uninduced cells) and were unable to confirm 
increased mitochondrial volume in these cells. However, these results 
were based on knock-down of AKT2 and the time points for evaluation of 
the effects differ greatly from our own. It is possible that the effect is not 
yet detectable or that Nb8 specifically blocks certain AKT2 functions and 
elicits different effects than an AKT2 knockdown. 
The role of AKT2 in breast cancer cell migration and metastasis has 
been well established [20,21,27,28,33,39]. GO term analysis of differ-
entially regulated proteins identified several enriched cellular compo-
nents, biological processes and molecular functions related to the actin 
cytoskeleton and cell migration. The phoshorylation of ZYX S308 and 
PARVA S4/8 is known to affect cell migration, but the function of the 
majority of the phosphosites identified in our experiments has not yet 
been elucidated [84,85]. Our results show AKT2 modulation by Nb8 
affects FAs in MDA-MB-231 cells. Organized complexes of FAs and stress 
fibers, which are observed at the leading edge of migrating cells, are not 
found in Nb8-expressing cells but were still present in MK-2206-treated 
cells. Although the down-regulation of PALLADIN, as was observed in 
AKT2 ablated cells, could explain the loss of stress fibers, PALLADIN 
levels were unchanged in Nb8-expressing cells (Supplementary 
Fig. S13). This suggests that maintaining PALLADIN expression does not 
require full AKT2 activity and that a full protein knockdown is required 
to elicit this effect. It also appears that a complete inhibition of the AKT 
family by MK-2206 does not have the same effect on the cytoskeleton in 
MDA-MB-231 cells, which is likely due to the opposite functions of AKT1 
and AKT2 in breast cancer cell migration. These results help explain how 
AKT2-specific signalling promotes cell migration in breast cancer cells. 
5. Conclusions 
In this study we have used a novel approach to interfere with AKT2. 
An isoform-specific Nb, which targets the HM, enabled us to study the 
effect of AKT2 modulation in cells without affecting AKT2 expression 
levels. The HM is, to our knowledge, a previously unexplored epitope for 
AKT inhibition. Here, we show the importance of the HM in AKT2 sig-
nalling and the cellular processes affected by blocking this domain 
(Fig. 9). Using high-throughput proteomics approaches we were able to 
identify proteins regulated by AKT2 further downstream in the pathway 
and the cellular processes which were affected by Nb8’s modulation of 
AKT2 activity. We show that, in MDA-MB-231 cells, AKT2 is the domi-
nant isoform in cell cycle regulation but, given the results from other 
studies, think it is unlikely that this process is regulated solely by AKT2. 
We confirmed AKT2’s role in autophagy and identified PTM events that 
occur on induction of autophagy. Finally, we identified an isoform- 
specific mechanism by which AKT2 regulates focal adhesions, which 
could affect the ability of cancer cells to migrate and metastasise. In 
summary, our results confirm AKT2 and the HM as a bona-fide target for 
cancer therapy. In contrast to techniques that down-regulate protein 
expression, Nb8 or its epitope can aid in the rational development of an 
AKT2-specific inhibitor or be used in the screening for small-molecules 
that target the AKT2 HM [86,87]. 
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STRING interactions. A dashed line indicates 
events that were not detected in this study, but 
are known to be a part of the AKT signalling 
pathway. The box marked “X” indicates the 
missing link(s) between AKT and the differen-
tially regulated proteins. An arrow and t-bar 
indicate activating and inhibiting modifica-
tions, respectively. Lines ending in dots indicate 
a protein-protein interaction. þp = phosphor-
ylation, þexp = increased expression and loc =
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